Meda acquires Treo
Meda has agreed to acquire three well-established Nordic OTC drugs from McNeil AB/Cilag GmbH International, members of the Johnson & Johnson Consumer Companies. Treo is the main drug. Annual sales for all three products total approximately 210 MSEK. Meda will acquire all rights to the drugs. The purchase price is 82 MEUR and the transaction is expected to be finalized within a couple of weeks. "Meda’s position within OTC drugs in the Nordic region has strengthened significantly in the last year. Meda becomes the largest company within prescription free pharmaceuticals in Sweden